Dobrin

Quick links to important sections

Dobrin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dobrin

Property Description
Active ingredient Sulpiride
Forms Tablet, Capsule, Oral solution, Intramuscular injection
Pharmacological class Antipsychotic Agent, Neuroleptic
General purpose To stabilize thought and emotional processes
Origin Synthetic (Substituted benzamide derivative)

What Type of Medicine is Dobrin (Sulpiride)?

Dobrin is a medicinal product whose active substance is Sulpiride, an Antipsychotic Agent. It is a synthetic compound belonging specifically to the substituted benzamide chemical family, a structure that is recognized for its ability to selectively influence dopamine pathways.

This classification places Sulpiride within the broader group of neuroleptics, which are used to help manage severe mental disturbances that affect perception and emotional stability. Unlike some older agents, Sulpiride is noted for its dose-dependent effects, offering varied profiles depending on the concentration administered. It is fundamentally a single active ingredient product, relying exclusively on the action of Sulpiride.

Composition and Available Forms of Dobrin

The medicine is composed solely of the active chemical ingredient, Sulpiride, suspended within a solid matrix or an aqueous solution, which serves as the inactive base/vehicle of the preparation.

Sulpiride is made available in several pharmaceutical forms to facilitate appropriate administration. These forms include oral preparations such as tablets and capsules, a liquid oral solution, and a formulation intended for intramuscular injection. Consequently, the primary routes of administration for Dobrin are oral for systemic management and intramuscular when rapid therapeutic effect is required. This wide array of formulations allows for tailored delivery to the patient's immediate need.

General Purpose of Sulpiride in Neuropsychiatry

The general purpose of Sulpiride is to help rebalance certain chemical signals in the brain, offering stabilization for psychological symptoms. The medication achieves this by acting as a dopamine receptor antagonist, primarily modulating the activity of dopamine—a critical neurotransmitter—at the D2 and D3 receptor sites. By stabilizing this signaling, the medicine is used in clinical practice to support individuals experiencing disrupted thought patterns or agitation. This mechanism provides a foundational benefit by supporting the restoration of more typical psychological function.

What side effects are possible with Dobrin?

The safety profile for Dobrin (Sulpiride) is organized and published in official regulatory documents, classifying possible effects by frequency and the body system affected.

Adverse Reaction Scope

Category Documented Characteristics
Frequency-Classified Common (up to 1 in 10): Hyperprolactinaemia, Sedation, Extrapyramidal disorder, Weight gain, Insomnia, Constipation. Rare (up to 1 in 1,000): Ventricular arrhythmia, Oculogyric crisis. Not Known: Neuroleptic Malignant Syndrome, Agranulocytosis, Sudden death, VTE.
System-Organ Classes Reactions primarily affect the Nervous System, Reproductive System, Endocrine System, Cardiac System, and Blood and Lymphatic System.
Serious Adverse Reactions Officially documented critical risks include Neuroleptic Malignant Syndrome (NMS), QT interval prolongation, Torsade de pointes, and the risk of Venous Thromboembolism (VTE).
Population Safety Notes An increased risk of death and cerebrovascular events is noted in older adults with dementia-related psychosis. Caution is advised for patients with a history of epilepsy and for those with risk factors for diabetes mellitus.
Exposure-Related Patterns Tardive dyskinesia is a risk reported after administration exceeding three months. Acute withdrawal symptoms may occur following abrupt cessation of treatment.
Safety Restrictions The medicine is contraindicated in cases of pre-existing prolactin-dependent tumours and phaeochromocytoma.

Connection to the Overall Safety Profile

This systematic documentation establishes the medicine’s risk profile by formally defining the likelihood of adverse events and highlighting rare but serious risks, such as life-threatening cardiac conditions. The profile also formally notes specific constraints and patient populations where caution is warranted, based on government-approved labeling.

Overdose and Emergency Response

The official regulatory profile for a Dobrin (Sulpiride) overdose documents serious and potentially life-threatening clinical manifestations. These presentations often involve the central nervous system, leading to signs such as agitation, confusion, altered state of consciousness, and progression to coma. Severe extrapyramidal symptoms are also documented, including muscle rigidity, trismus (lockjaw), and torticollis (twisted neck). Vomiting is also listed as a manifestation in overdose cases.

A primary concern listed in official labeling is the potential for life-threatening cardiotoxicity. Overdose may cause severe cardiovascular events, specifically QT interval prolongation, which carries a high risk of developing malignant ventricular arrhythmias, including Torsade de pointes and potential cardiac arrest. Other severe outcomes described in regulatory documents include convulsions and the possible development of Neuroleptic Malignant Syndrome (NMS).

Emergency Action and Management

Due to the risk of severe and potentially fatal cardiac and neurological events, regulatory guidance mandates that individuals must seek immediate medical attention upon any suspicion of overdose. The official labeling states that no specific antidote is known for Sulpiride. Management is therefore limited to symptomatic and supportive treatment. Required supportive actions include close supervision of vital functions and continuous cardiac monitoring until the patient achieves recovery. Anticholinergics are the officially described procedure for managing severe extrapyramidal symptoms.

Therapeutic Uses of Dobrin

What Dobrin Treats: Main Uses and Benefits

The medication is commonly used across therapeutic domains where additional symptomatic support is needed, primarily in situations involving certain distressing symptoms related to thought and mood disturbances. This intervention generally assists with maintaining functional stability when symptoms become more noticeable.

The primary therapeutic areas involve the management of schizophrenia (acute and chronic) and related psychotic states, and it is also relevant in conditions characterized by periods of heightened symptoms, including specific manifestations of Major Depressive Disorder, vertigo (dizziness), and somatoform disorders.

The medication helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load during symptomatic periods.

It is often used when symptoms intensify and supportive relief is needed, supporting the patient during difficult episodes by easing distress and managing disruptive manifestations across different categories of conditions.


Quick Fact: Relief for Disruptive Psychological Symptoms

Dobrin supports the management of both positive psychotic symptoms (like delusions and hallucinations) and negative psychotic symptoms (like apathy and social withdrawal). It is also considered relevant for easing inner tension associated with affective disorders.

Eligibility and Restrictions for Use

Dobrin (a representative drug of the amide-type local anesthetic class) is subject to strict eligibility rules documented by governmental regulatory agencies.

Populations Who Must Not Use Dobrin (Contraindications)

The medicine is formally contraindicated and must not be used in the following circumstances:

  • Known Hypersensitivity: Patients with a documented allergy (hypersensitivity) to Dobrin, to any other amide-type local anesthetic, or to other components of the solution.
  • Specific Procedures: Its use is prohibited for obstetrical paracervical block anesthesia and for intravenous regional anesthesia (Bier Block).

Eligibility Restrictions and Special Considerations

Official labeling mandates that use be restricted or carefully considered in certain populations:

Population Group Eligibility Status / Restriction
Pediatric Patients Not recommended in children under 12 years of age due to limited safety and efficacy data.
Elderly Patients Use with caution; a reduced dose may be necessary. These patients may be at greater risk for systemic toxicity, particularly if they have impaired kidney function.
Severe Organ Impairment Patients with moderate to severe hepatic impairment or impaired renal function require caution and close monitoring due to an increased risk of toxic plasma concentrations.
Concentration Use The highest drug concentration (0.75%) is not recommended for obstetrical anesthesia.

Dobrin is generally intended for use in adults (18 years and older) for local or regional anesthesia procedures, provided none of the documented contraindications or specific restrictions apply.

What should I know about interactions with other medicines?

Dobrin's interaction profile is officially categorized by regulatory authorities into several critical domains based on pharmacodynamic and pharmacokinetic effects.

Formal Prohibitions and Antagonism

Co-administration of Sulpiride with Levodopa or other Dopamine Agonists is formally designated as contraindicated in regulatory documents due to the risk of reciprocal pharmacodynamic antagonism of effects.

Synergistic Risks (CNS and Cardiac)

The combination with other CNS Depressants (such as sedatives or narcotics) results in an additive pharmacodynamic effect, leading to enhanced central sedation. A serious interaction risk is documented with medicinal products that prolong the QT interval or induce bradycardia (e.g., certain antiarrhythmics, beta-blockers, or hypokalemic agents). This combination increases the official risk of serious ventricular arrhythmias, including Torsades de pointes. Co-administration with Antihypertensive Agents may result in an enhanced antihypertensive effect and increased likelihood of postural hypotension.

Pharmacokinetic and Timing Restrictions

Antacids (containing aluminium or magnesium) and Sucralfate officially lead to decreased absorption of Sulpiride. To mitigate this pharmacokinetic interference, a mandatory two-hour separation is required; Sulpiride must be administered two hours before these agents. The medicine is also documented as neither inhibiting nor inducing CYP450 enzymes.

Other Substance Interactions

The regulatory profile advises that the consumption of Alcohol (Ethanol) must be avoided as it enhances the sedative effects of the medicine.

Mechanism of Action

Selective Dopamine Receptor Modulation

Dobrin's mechanism is anchored in the selective antagonism (blockade) of Dopamine D2 and D3 receptors within the Central Nervous System (CNS), particularly targeting key structures in the mesolimbic pathway. This molecular action modifies dopamine signaling dynamics, which are critical for modulating central nervous system information throughput.


Concentration-Dependent Functional Shift

A unique aspect of its action is the concentration-dependent functional shift. At lower concentrations, the drug preferentially blocks presynaptic D2 autoreceptors, which acts as a regulatory brake removal and results in a functional increase of dopaminergic signaling. Conversely, at higher concentrations, the blockade of less sensitive postsynaptic D2 receptors dominates, functionally reducing overall D2-mediated signaling.


Systemic Pathway Modulation

This D2 antagonism is not confined to cognitive pathways. The mechanism also modulates the Tuberoinfundibular pathway, removing the inhibitory control on prolactin secretion and leading to its increase. Furthermore, D2 antagonism influences the Chemoreceptor Trigger Zone (CTZ), which is the biological basis for its D2 receptor-mediated antiemetic action. This mechanism leads to systemic adjustments that define the molecule's overall functional profile.

Dosage and Administration Information

How Dobrin (Sulpiride) is Used

Dobrin is administered using defined routes, dosages, and conditions for use. The drug is primarily available for oral use as tablets, capsules, or an oral solution, although an intramuscular injection is also an established route for certain clinical contexts.

Standard Dosing and Frequency

Dosing parameters include a broad range of oral doses, which are typically administered in divided doses, generally twice daily. For the management of positive symptoms of schizophrenia, the daily dose may range from a typical starting regimen of 800 mg up to a maximum of 2400 mg per day. For negative symptoms, doses are generally maintained below 800 mg daily. For other uses, lower daily doses between 50 mg and 300 mg are commonly applied.

Administration Conditions and Course

Oral tablets must be swallowed whole with water and should not be crushed or chewed. To avoid potential sleep disruption, the final dose of the day should not be taken after 4 p.m. The medicine can be taken with or without food. However, to ensure proper absorption, Sulpiride must be administered at least two hours before antacids, such as those containing sucralfate.

Treatment is typically divided into an acute phase (up to six weeks) followed by a long-term maintenance regimen as required. When discontinuing the medicine, the dosage must be gradually reduced over a period of time, as part of a structured withdrawal.

Population-Specific Adjustments

Dosage adjustments are utilized for individuals with renal impairment. The dose or the dosing interval is reduced and extended, respectively, in proportion to the degree of kidney function impairment. Although older adults may receive similar doses, reduction is required if they exhibit concurrent renal impairment.

Recent Clinical Evidence

Research Evidence: Overview of Clinical Studies for Dobrin (Sulpiride)


Evidence for Use in Schizophrenia (Acute and Chronic)

Research where Dobrin (Sulpiride) was studied for conditions characterized by fluctuating or episodic manifestations, such as schizophrenia, includes both Randomized Controlled Trials (RCTs) and larger reviews. Researchers examined outcomes related to systemic or functional imbalance in adult populations. The core research studied changes in standardized measures of positive symptoms (like delusions or hallucinations) and negative symptoms (like social withdrawal or apathy), alongside measures of overall clinical state and the risk of symptoms returning.

Studies report how symptoms evolved in the observed populations, with findings describing patterns observed in studies that include comparisons against a placebo or against other established medicines used for these conditions. Reported outcomes for the acute management phase were predominantly based on evaluations lasting three months or less. Evidence remains heterogeneous due to variations in study methodology and the specific control or comparison used.

Evidence for Use in Major Depressive Disorder

Sulpiride was studied for Major Depressive Disorder in controlled clinical studies and comparative trials relevant for assessing short-term or episodic symptom patterns. These studies monitored outcomes reflecting daily functioning or activity level, such as changes in overall depressive symptoms, along with specific features like inner tension or psychomotor slowness.

Studies report measurable short-term changes in depression scale scores and specific symptom markers across the treatment period. A key limitation is that the research base includes a relatively high proportion of older clinical studies. Additionally, the follow-up durations were limited, meaning there is limited information for the stability and evolution of the reported changes over an extended period.


The Study Landscape: What Is Still Uncertain about Dobrin

The current research contributes to the broader evidence landscape but also highlights areas where more data are needed. The certainty remains low for several aspects of the medicine’s clinical use. Specifically, the body of high-quality comparative evidence against a full range of currently utilized standard treatments is lacking. There is limited information for long-term outcomes across all indications. Study results reflect the specific conditions and populations under which they were conducted, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Dobrin (FAQ)

Q: What conditions is Dobrin officially approved to treat?

A: Official regulatory documents state that Dobrin is approved for the treatment of both acute and chronic schizophrenia.


Q: What side effects are listed as generally minor and non-urgent?

A: Official product information lists several common effects, which are reported to affect up to 1 in 10 people. These frequently include feeling sleepy, experiencing weight gain, or having difficulty sleeping. Other common reported reactions include movement issues such as tremor or stiffness, and changes like breast discomfort or abnormal milk production.


Q: Are there any common over-the-counter medicines known to interact with Dobrin?

A: Official drug information indicates that products containing antacids (often used for indigestion) and sucralfate are known to interfere with how Dobrin is absorbed by the body. The official guidance recommends that these products be administered at least two hours apart from Dobrin to minimize potential interference.


Q: Is it necessary to avoid certain foods or beverages while taking Dobrin?

A: According to the official warnings, the consumption of alcohol is advised to be avoided while taking this medicine. Alcohol is documented to enhance the medicine's effects on the central nervous system, which may increase the risk of certain side effects.


Q: What factors might cause Dobrin to take longer than average to work?

A: Regulatory information indicates that the body eliminates this medicine primarily through the kidneys. If a person has reduced kidney function, dosage adjustments or extended intervals are officially mandated, which could potentially affect the time it takes for the drug's full therapeutic effect to be achieved.


Q: What is the expected range of effectiveness described in research studies?

A: Studies and official information describe effectiveness in terms of improvement in specific symptoms. This often includes the reduction of positive symptoms (such as delusions) and changes in negative symptoms (such as apathy or social withdrawal).


Q: Are there any specific activities or hobbies to avoid while taking Dobrin, such as operating heavy machinery?

A: Official patient caution advises that the potential for side effects like dizziness and drowsiness may impair the ability to drive or operate heavy machinery. Patients are therefore advised to exercise caution or avoid these activities, particularly when treatment is initiated.


Q: How quickly do side effects from Dobrin usually appear after starting treatment?

A: Some side effects, such as sleepiness or stiffness, may become apparent shortly after starting treatment or over the first couple of weeks. Other, more serious reactions are listed in regulatory documents as critical risks that could occur acutely.


Q: Is a mild headache a typical reaction when first taking Dobrin?

A: While not always listed among the most common effects, a headache is an adverse reaction that has been reported by some individuals taking this medicine.


Q: What is the pregnancy category for Dobrin, according to regulatory documents?

A: Official regulatory information indicates that due to insufficient data in humans, use of this medicine during pregnancy is generally reserved for strict clinical indications. Newborns of women treated near term are advised to be monitored for possible effects after birth.


Q: Is there information about using Dobrin while breastfeeding?

A: Regulatory documents confirm that the medicine is found in breast milk. Because the potential consequences for the nursing infant are unclear, official information generally advises against breastfeeding while undergoing treatment with this medicine.


Q: How long does it usually take for Dobrin to start having a noticeable effect?

A: The time it takes to notice improvement can vary based on the symptoms being addressed. If the medicine is used to treat hallucinations, noticeable improvement may begin after approximately one week.


Q: When can a person typically expect to feel the full effect of Dobrin?

A: For full noticeable effects on mood and behavior symptoms, official information suggests it may take up to six to eight weeks of consistent treatment. The prescribed regimen should be followed during this period.


Q: How long does a single dose of Dobrin stay in the body before it is eliminated?

A: Regulatory documents report that the elimination half-life of a single dose is approximately six to eight hours. This figure describes the time it takes for half of the medicine to be removed from the bloodstream.


Q: Where can I find the official regulatory information, such as the full package insert, for Dobrin?

A: The official regulatory documentation is called the Summary of Product Characteristics (SmPC) or the Patient Information Leaflet (PIL). These documents are typically available on the websites of national drug regulatory authorities.


Q: Is there a standard procedure for what to do after missing a dose of Dobrin?

A: The patient information leaflet provides general guidance regarding a missed dose. The standard advice described is to take the dose as soon as it is remembered unless the next scheduled dose is almost due, in which case the missed dose is usually skipped.


Q: Is Dobrin known to be a habit-forming or addictive medicine?

A: Official documentation notes that acute withdrawal symptoms may occur if the medicine is stopped abruptly. These potential effects may include feeling sick, sweating, difficulty sleeping, or experiencing movements that cannot be controlled.


Q: What should a patient know about how Dobrin is eliminated from the body?

A: The medicine is eliminated from the body primarily by the kidneys (known as the renal route). Most of the active drug is reported to be excreted unchanged.


Q: Are there any laboratory tests or monitoring that is generally needed when starting Dobrin?

A: Official guidelines generally recommend monitoring a patient's weight or BMI, blood lipids, and blood glucose/HbA1c levels. Furthermore, monitoring of the heart (ECG) is often advised if the patient exhibits risk factors for certain cardiac issues.

How should Dobrin be stored and disposed of?

How to Store and Dispose of Dobrin (Sulpiride)

Official regulatory documents mandate specific conditions for the storage and disposal of Sulpiride, the active ingredient in Dobrin, to maintain stability and ensure safety.

Mandatory Storage Conditions

Requirement Instruction
Temperature Limit Store the product below 25 C; storage above this temperature is prohibited.
Packaging Keep the medicine in its original container or outer carton for protection from light and moisture.
Safety It must be stored strictly out of the sight and reach of children.

Disposal Instructions

Properly discard unused or expired Dobrin in accordance with local requirements for medicinal products. The medication must not be thrown away with household waste or disposed of via wastewater, such as flushing down the toilet or pouring down a sink. Additionally, any contents remaining in single-use injectable ampoules must be discarded immediately after administration.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dobrin found in:

A-Z Index: